The 5 most overpaid CEOs in healthcare ranked

Amy Baxter | | Health Exec | Management
Money

Healthcare companies have become some of the largest businesses in the U.S. and worldwide, with the sector expected to grow to roughly 20% of the U.S. GDP by 2027. Leaders of these companies have also seen their salaries explode over the last several years as well as other compensation from stocks and bonuses.

With such high earners in the sector, As You Sow decided to rank the 100 most overpaid CEOs across all sectors­­––and included several healthcare names to know.

Here are the top 5 overpaid healthcare CEOs ranked:

Joseph Hogan, CEO of medical device company Align Technologies

  • Total payment: $41,758,338
  • Overpayment: $27,119,793
  • Median worker pay: $13,180

Stephen MacMillan, chairman, president and CEO of medical technology company Hologic

  • Total payment: $42,020,142
  • Overpayment: $29,140,855
  • Median worker pay: $87,845

Michael Neidorff, CEO of Centene

  • Total payment: $26,122,414
  • Overpayment: $12,561,836
  • Median worker pay: $66,021

Alex Gorsky, CEO of Johnson & Johnson

  • Total payment: $20,097,572
  • Overpayment: $7,551,949
  • Median worker pay: $75,000

Kent Thiry, CEO of Davita

  • Total payment: $32,017,501
  • Overpayment: $20,477,984
  • Median worker pay: $60,889

See the full list here.

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.